BioSpace News Archive

PENTAX Medical announces the addition of new dedicated electrosurgical and argon plasma coagulation (APC) platforms – the ENDO ARC and ENDO PLUS – to its therapeutic accessories range.

Arix Bioscience plc (LSE:ARIX) (“Arix” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, has been reappointed as Chief Executive Officer and will re-join the Arix Board.

Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced that it will participate in the following investor conferences in February and March

Silicon Valley Bank releases 10th annual Startup Outlook report series based on nearly 1,400 survey responses from technology and healthcare executives in major innovation hubs

Dacarba LLC, an Opportune LLP company, is pleased to announce that it has launched a proprietary data-driven prescriptive analytics software, Medical Diagnosis Accuracy Reporting, which paints an accurate and transparent picture of each patient’s comorbidities for providers and improves quality measurement.

The Texas Mesothelioma Victims Center is the best branded resource in Texas for a US Navy Veteran receiving the very best possible financial compensation-if they have been diagnosed with mesothelioma or asbestos exposure lung cancer.

Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.”

Reference is made to the stock exchange announcement on 18 February 2019 where Nordic Nanovector ASA (the “Company”) announced that the extraordinary general meeting of the Company had granted the Board of Directors an authorisation to increase the share capital of the Company in connection with a repair offering of up to 777,777 new shares (the “Offer Shares”)

IT Staffing Company Rebrands as Part of Parent Company Structure

The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports.